- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on ALK or ROS1-positive NSCLC
Total 35408 results
-
AkesoNot yet recruitingLocally Advanced or Metastatic NSCLCChina
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.UnknownLocally Advanced or Metastatic NSCLCChina
-
Genentech, Inc.RecruitingMelanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCCKorea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingHase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)Advanced or Metastatic NSCLCChina
-
AstraZenecaDaiichi SankyoRecruitingAdvanced or Metastatic NSCLCUnited States, Taiwan, Italy, Spain, Poland, Japan, Belgium, Turkey, France, Korea, Republic of
-
AstraZenecaActive, not recruitingAdvanced or Metastatic NSCLCRussian Federation
-
Tianjin Medical University Cancer Institute and...Not yet recruitingNSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
-
Shandong Provincial HospitalUnknown
-
Samsung Bioepis Co., Ltd.CompletedHER2 Positive Early or Locally Advanced Breast CancerCzechia
-
Vestre Viken Hospital TrustOslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaboratorsRecruitingOncology | NSCLC Stage IV | NSCLC, Stage IIINorway
-
PfizerOxOnc Development LPCompletedNon Small Cell Lung Cancer | Crizotinib | ROS1 Proto OncogeneKorea, Republic of, China, Taiwan, Japan
-
Japan Breast Cancer Research GroupChugai PharmaceuticalUnknownHER2-positive Locally Advanced or Metastatic Breast CancerJapan
-
Baodong QinUnknownNSCLC Stage IV | Anlotinib | EGFR T790M-negative | JS001China
-
Żelazna Medical Centre, LLCFoundation for St. Sophia Specialist Hospital in WarsawRecruitingFetal Position and Presentation AbnormalitiesPoland
-
University of BolognaUnknownVacuum Extraction; Failure, Affecting Fetus or Newborn | Persistent Occiput Posterior Position During Labor | Complication of DeliveryItaly
-
National Taiwan University HospitalRecruiting
-
Maastricht University Medical CenterKU Leuven; University College, London; Erasmus Medical Center; Catholic University... and other collaboratorsActive, not recruitingNSCLC Stage IV | Metastatic DiseaseNetherlands, Belgium, United Kingdom, Germany, France, Italy
-
iTeos Belgium SARecruitingMetastatic NSCLC | Stage III NSCLCUnited States, Belgium, Spain, Switzerland, Italy, France, Canada, Poland, Czechia
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
Yonsei UniversityUnknownNon-small Cell Lung Cancer Harboring ROS1 RearrangementKorea, Republic of
-
Hoffmann-La RocheRecruitingInoperable, Locally Advanced or Metastatic, ER-positive Breast CancerUnited States, Korea, Republic of, Spain, Australia, Israel
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
-
Chinese University of Hong KongPamela Youde Nethersole Eastern HospitalCompleted
-
Shanghai Chest HospitalGeneplus-Beijing Co. Ltd.; Guangzhou Burning Rock Medical Examination Institute... and other collaboratorsUnknownNSCLC | Malignant HydrothoraxChina
-
Massachusetts General HospitalNational Cancer Institute (NCI)CompletedNon-small Cell Lung Cancer Metastatic | Targetable Oncogenes (EGFR, ALK, ROS1)United States
-
Henan Cancer HospitalUnknownAdvanced NSCLC With EGFR MutationChina
-
Centre Francois BaclesseHoffmann-La Roche; Groupe Français de Pneumo-CancérologieTerminatedNSCLC Patients With EGFR Activating MutationFrance
-
UNICANCERARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research GroupActive, not recruitingER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI StatusFrance
-
University of California, IrvineWithdrawnAnesthetized Healthy Patients (ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries | Anesthetized Patient With Severe Systemic Disease (ASA 3 or 4)United States
-
Shanghai Children's HospitalChildren's Hospital affiliated to Chongqing Medical University; Xuzhou maternal...Not yet recruitingPremature Infants | NICU Infants | Conventional NBS-positive Infants
-
AIPING ZHOUNot yet recruitingImmunotherapy | Sintilimab | Locally Advanced Solid Tumor | Oxaliplatin | HER2-positive | Gastric or Gastroesophageal Junction Adenocarcinoma | S-1China
-
National University Hospital, SingaporeUnknown
-
Nasser HannaGenentech, Inc.TerminatedNSCLC Stage IV | NSCLC, RecurrentUnited States
-
Fengxi SuUnknownBreast Cancer Patients in Premenopausal | Estrogen and/or Progesterone Receptor PositiveChina
-
Shanghai JMT-Bio Inc.Active, not recruitingLocal Advanced or Metastatic NSCLC | Harboring EGFR Common MutationChina
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
AmgenParexelWithdrawnMetastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
National Health Research Institutes, TaiwanTerminatedHead and Neck Cancer | NSCLCTaiwan
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterCompletedRelapsed or Refractory EBV-and CD30-positive LymphomasKorea, Republic of
-
GlaxoSmithKlineCompleted
-
AHS Cancer Control AlbertaEMD SeronoActive, not recruitingSquamous Cell Carcinoma of the Cervix | Cancer That is Associated With a Chronic Viral Infection | p16 Positive SCCHN | p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva | p16 Positive Squamous Cell Carcinoma of the Penis | p16 Positive Squamous Cell Carcinoma of the Anus or Anal... and other conditionsCanada
-
Seoul National University HospitalCompletedDurvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLCKorea, Republic of
-
Xuanzhu Biopharmaceutical Co., Ltd.RecruitingROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung CancerChina
-
ETOP IBCSG Partners FoundationRoche Pharma AGActive, not recruitingEGFRmutant Stage IIIB/C or IV Non-squamous NSCLCSingapore, Spain, Korea, Republic of, Switzerland, Germany
-
Johns Hopkins UniversityNational Institutes of Health (NIH)CompletedHuman Immunodeficiency Virus Positive or NegativeUnited States
-
Novartis PharmaceuticalsRecruitingALK Positive MalignanciesGermany, France, Australia, Belgium, Italy, Korea, Republic of, Poland, China, United States, Taiwan, Brazil, Bulgaria, Hong Kong, Japan, Lebanon, Malaysia, Spain, Russian Federation, Colombia, Singapore, Czechia